Elsevier

Kidney International

Volume 61, Issue 1, January 2002, Pages 324-335
Kidney International

Dialysis – Transplantation
Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients

https://doi.org/10.1046/j.1523-1755.2002.00119.xGet rights and content
Under an Elsevier user license
open archive

Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients.

Background

It is thought that transforming growth factor-β1 (TGF-β1) might be a key inhibitor of atherogenesis in non-uremic patients. We evaluated the intra- and post-dialytic serum levels of TGF-β1 in uremic patients to assess if TGF-β1 is an independent risk factor for cardiovascular diseases, and if any correlation exists between TGF-β1 and any yet known atherosclerotic risk factors.

Methods

We studied 155 patients who were on regular hemodialysis, with or without clinically significant atherosclerotic vascular disease. Forty-one apparently healthy people were enrolled as a control group. TGF-β1 was evaluated during the midweek dialysis session, at times 0, 30, and 120 minues, at the end of the session, and 3 hours after the session's end. All hitherto known atherosclerotic risk factors also were evaluated. The investigation was performed over a 24-month follow-up.

Results

TGF-β1 values (mean ± SD) in dialysis patients were 26.64 ± 7.0 ng/mL (N = 155) compared with 42.31 ± 6.0 ng/mL in the control group (N = 41, P < 0.0001). A weak inverse correlation emerged between TGF-β1 and age (r = -0.28), TGF-β1 and lipoprotein(a) [Lp(a); r = -0.35], TGF-β1 and C-reactive protein (CRP; r = -0.27), and TGF-β1 and plasminogen activator inhibitor-1 (PAI-1; r = -0.41). TGF-β1 also correlated with albumin (r = 0.31). In the coronary heart disease (CHD) group (N = 32) the TGF-β1 was 26.2 ± 4.9 ng/mL; in the cerebrovascular disease (CVD) group (N = 8) it was 26.7 ± 3.7 ng/mL and in the peripheral vascular disease (PVD) group (N = 9) it was 25.4 ± 1.7 ng/mL. In dialysis patients with no cardiovascular disease (N = 80) TGF-β1 was 35.1 ± 6.8 ng/mL (P < 0.0001 vs. CHD, CVD and PVD patients). TGF-β1 was significantly lower among those patients with triple coronary vessel disease than with the other CHD patients. The Cox analysis demonstrated that a 1 ng/mL reduction in TGF-β1 concentration was associated with a 9% increase in the relative risk of a cardiovascular event.

Conclusions

TGF-β1 was significantly reduced in hemodialysis patients, in particular in those with severe cardiovascular disease. Baseline TGF-β1, diabetes mellitus and serum albumin levels proved to be the only independent contributors to atherosclerotic risk in dialysis patients.

Keywords

atherosclerosis
cardiovascular diseases
uremia
hemodialysis
ischemic heart disease
vascular complication

Cited by (0)